Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer

Published:2017-10 Issue:10 Volume:12 Page:1552-1560
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yang James Chih-Hsin,Ou Sai-Hong Ignatius,De Petris Luigi,Gadgeel Shirish,Gandhi Leena,Kim Dong-Wan,Barlesi Fabrice,Govindan Ramaswamy,Dingemans Anne-Marie C.,Crino Lucio,Lena Herve,Popat Sanjay,Ahn Jin Seok,Dansin Eric,Golding Sophie,Bordogna Walter,Balas Bogdana,Morcos Peter N.,Zeaiter Ali,Shaw Alice T.

Funder

National Institute for Health Research Biomedical Research

F. Hoffmann-La Roche, Ltd

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap);Dearden;Ann Oncol,2013

2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

3. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

4. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J Clin Oncol,2015

5. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer;Weickhardt;J Thorac Oncol,2012

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung Cancer;Clinical Lung Cancer;2024-04

2. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29

3. Somatic mutation: Pharmacogenomics in oncology care;Biomarkers in Cancer Detection and Monitoring of Therapeutics;2024

4. Small cell lung cancer;Lung Cancer;2024

5. Efficacy and safety of iruplinalkib (WX‑0593) on non‑small cell lung cancer with SPECC1L‑ALK fusion: A case report;Experimental and Therapeutic Medicine;2023-12-05